Compare Lululemon Athletica Inc (LULU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Merck & Co., Inc. — how do they compare? Lululemon Athletica Inc trades at $94.41 (market cap $10.27B), while Merck & Co., Inc. trades at $146.19 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 34.2× Lululemon Athletica Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and Merck & Co., Inc. for 98 Days on average.
| LULU | MRK | |
|---|---|---|
Market Cap | $10.27B | $351.28B |
Volume | 4,392,324 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $156.43 |
52-Week Low | $91.88 | $82.49 |
Typical Hold Time | 105 Days | 98 Days |
Enterprise Value | $11.02B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.21, down 54% year-to-date and near its 52-week low. Despite strong profitability with a 56.11% gross margin and 30.9% ROE, recent revenue declines and a bearish technical signal have pressured shares. Multiple law firms are investigating potential securities fraud following the stock's sharp drop, while earnings have consistently beaten expectations.
The outlook remains challenged by growth concerns and governance scrutiny, though a low P/E of 7.63 offers valuation support. Risks include competitive pressures and ongoing legal probes, but analyst consensus targets $97.67, suggesting moderate upside if execution improves.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
